Residual Abdominal Lymphadenopathy after Intensive Frontline Chemoimmunotherapy Is Associated with Inferior Outcome Regardless of MRD Status in Advanced Chronic Lymphocytic Leukemia (CLL)

MLA

Barbara Eichhorst, et al. “Residual Abdominal Lymphadenopathy after Intensive Frontline Chemoimmunotherapy Is Associated with Inferior Outcome Regardless of MRD Status in Advanced Chronic Lymphocytic Leukemia (CLL).” Blood, vol. 132, Nov. 2018, p. 4430. EBSCOhost, https://doi.org/10.1182/blood-2018-99-113280.

APA

Barbara Eichhorst, Kirsten Fischer, Elisabeth Lange, Peter Dreger, Georg Hess, Hartmut Döhner, Sebastian Böttcher, Michael Kneba, Valentin Goede, Clemens-Martin Wendtner, Stephan Stilgenbauer, Moritz Fürstenau, Anna-Maria Fink, Matthias Ritgen, Michael Hallek, Jasmin Bahlo, & Martin Dreyling. (2018). Residual Abdominal Lymphadenopathy after Intensive Frontline Chemoimmunotherapy Is Associated with Inferior Outcome Regardless of MRD Status in Advanced Chronic Lymphocytic Leukemia (CLL). Blood, 132, 4430. https://doi.org/10.1182/blood-2018-99-113280

Chicago

Barbara Eichhorst, Kirsten Fischer, Elisabeth Lange, Peter Dreger, Georg Hess, Hartmut Döhner, Sebastian Böttcher, et al. 2018. “Residual Abdominal Lymphadenopathy after Intensive Frontline Chemoimmunotherapy Is Associated with Inferior Outcome Regardless of MRD Status in Advanced Chronic Lymphocytic Leukemia (CLL).” Blood 132 (November): 4430. doi:10.1182/blood-2018-99-113280.